Liver Transplantation Utilizing Grafts Donated After Medical Assistance in Dying Is Feasible and Has Outcomes Comparable to Standard Donation

Organ donation following medical assistance in dying (MAiD), also known as euthanasia, is a relatively new practice both in North America and worldwide. A first comparison of liver transplantation using organs donated after MAiD in Canada has shown good patient survival with outcomes similar to standard donation after circulatory death. The findings from the new study in the Journal of Hepatology, published by Elsevier, highlight that this practice can help to meet the increasing demand for organs by expanding the donor pool, thereby saving more lives.

As of 2025, organ donation following MAiD is legalized in only a few countries, namely Australia, Belgium, Canada, Spain, and the Netherlands. Because it is so recent, there have been very limited data on whether livers donated after MAiD can be utilized with satisfactory outcomes.

This study involved the review of 313 liver transplants performed in six Canadian transplant centers with organs procured from donors following circulatory death determination between 2016 and 2023. The study compared outcomes of standard donation after circulatory death (type 3, 257 liver transplants) with donation after circulatory death after MAiD (type 5, 56 liver transplants). The results showed excellent outcomes in both groups and demonstrated similar survival rates between donation after circulatory death between groups.

“Our study provides the first large-scale Canadian experience, paralleling previous studies from Belgium and the Netherlands, showing that outcomes are positive, while also demonstrating the real impact that MAiD donation can have on the availability of organs,” says co-lead investigator A.M. James Shapiro, MD, PhD, Canada Research Chair and Director of Liver Transplantation at the University of Alberta, Edmonton, adding, “While not all individuals pursuing MAiD are suitable for donation for various reasons, we hope that our study will allow a better understanding of the potential role of organ donation following MAiD and how impactful it can be for saving lives of many people in their final act of generosity.”

Co-lead investigator Alessandro Parente, MD, PhD, Division of Transplantation, Department of Surgery, University of Alberta, Edmonton; Institute of Liver Studies, and King’s College Hospital, London, notes, “People who choose MAiD often face incurable illnesses, and it is a deeply personal and carefully regulated decision. Safeguards are in place to ensure that any choice about organ donation is made freely, without pressure or judgment. Organ donation after MAiD only occurs if the patient independently decides to make this ultimate gift, and this is strictly separated from their end-of-life care decision.”

Liver transplantation is a lifesaving procedure for patients affected by end-stage liver disease, acute liver failure, liver cancer, and well-selected genetic liver disorders. The incidence of liver diseases and the indications for liver transplantation are increasing. Thousands of patients are waiting for a transplant, but the number of available organs is far lower than the demand.

The findings of this study suggest that donation after MAiD could significantly expand the pool of available livers. This type of donation accounted for an almost 22% increase in donation after circulatory death activity in Canada, which translates to about eight additional livers for transplant each year over a seven-year period.

Professor Shapiro points out, “This is not just a number — it means more patients being removed from the waiting list, more lives saved, and better outcomes for people with liver diseases. In addition, other previous studies showed positive results for other organs such as heart, lungs, and kidneys donated after MAiD, highlighting the potential benefits for more life-saving procedures not limited solely to the liver.”

Dr. Parente concludes, “For many patients, the opportunity to donate their organs provides comfort in knowing they can leave a meaningful legacy, honor their wish to help others, and give the gift of life even at the end of their own journey. Donation can also bring comfort to families, knowing that their loved one was able to help others in such a meaningful way through this profound act of compassion.”

Notes for editors

The article is “Utilization of liver grafts obtained from donation after medical assistance in dying: a Canadian multicenter experience," by Alessandro Parente, Kevin Verhoeff, Samrat Ray, Markus Selzner, Trevor W. Reichman, Michael S. Bleszynski, Maja Segedi, Juan Glinka, Ephraim Tang, Olivia Ganescu, Magan Solomon, Jeffrey Barkun, Prosanto Chaudhury, Steven Paraskevas, George Zogopoulos, Santiago Rubio, Boris L. Gala-Lopez, Khaled Z. Dajani, and A.M. James Shapiro (https://doi.org/10.1016/j.jhep.2025.08.039). The article appears online in Journal of Hepatology, published by Elsevier.

The article is openly available at https://www.journal-of-hepatology.eu/article/S0168-8278(25)02478-X/fulltext.

Full text of the article is also available to credentialed journalists upon request; contact Freya Weise, MD, PhD, at +33 (1) 71 16 55 00 or hmsmedia@elsevier.com. Journalists wishing to interview the authors should contact Alessandro Parente, MD, PhD, at [email protected], or Jodie Andres on behalf of A.M. James Shapiro, MD, PhD, at [email protected].

The study was approved by the institutional health research ethics board at the University of Alberta Hospital (Edmonton, Alberta) with registration number Pro00133930. It was made possible thanks to the generosity of donors and the unwavering dedication of Canadian transplant organizations, to whom the authors wish to extend their heartfelt gratitude.

About the Journal of Hepatology

The Journal of Hepatology, the premier journal devoted to liver diseases, is the official journal of the European Association for the Study of the Liver (EASL). It publishes original papers, reviews, case reports, and letters to the Editor concerned with clinical and basic research in the field of hepatology. The journal has a 2024 Impact Factor of 33 (Source: Journal Citation Reports™ from Clarivate, 2025). www.journal-of-hepatology.eu

About EASL

In the fifty plus years since EASL was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading international liver association. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy. www.easl.eu

Acerca de Elsevier

Como líder mundial en información y análisis científicos, Elsevier ayuda a los investigadores y profesionales de la salud a hacer avanzar la ciencia y mejorar los resultados de salud en beneficio de la sociedad. Lo hacemos facilitando conocimientos y la toma de decisiones críticas con soluciones innovadoras basadas en contenido confiable y basado en evidencia y tecnologías digitales avanzadas habilitadas por IA. Hemos apoyado el trabajo de nuestras comunidades de investigación y atención médica durante más de 140 años. Nuestros 9500 empleados en todo el mundo, incluidos 2300 tecnólogos, se dedican a apoyar a investigadores, bibliotecarios, líderes académicos, financiadores, gobiernos, empresas intensivas en I+D, médicos, enfermeras, futuros profesionales de la salud y educadores en su trabajo crítico. Nuestras 2900 revistas científicas y libros de referencia icónicos incluyen los títulos más importantes en sus campos, incluidos Cell Press, The Lancet y Gray's Anatomy. Junto con Elsevier Foundation, trabajamos en asociación con las comunidades a las que servimos para promover la inclusión y la diversidad en la ciencia, la investigación y la atención médica en los países en desarrollo y en todo el mundo. Elsevier es parte de RELX, un proveedor global de herramientas de toma de decisiones y análisis basados ​​en información para clientes profesionales y comerciales. Para obtener más información sobre nuestro trabajo, soluciones digitales y contenido, visite www.elsevier.com.